Defining miRNA targets balancing simplicity with complexity

Circulation

Volumn 127, Issue 21, 2013, Pages 2075-2077

  Freedman, Jane E ^a   Tanriverdi, Kahraman ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MICRORNA; MICRORNA 378; MITOGEN ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

APOPTOSIS; CELL PROLIFERATION; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; HEART HYPERTROPHY; HUMAN; ISCHEMIC HEART DISEASE; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RNA TRANSCRIPTION;

CARDIAC; EDITORIALS; HYPERTROPHY; MICRORNAS; MYOCYTES;

ANIMALS; CARDIOMEGALY; MICRORNAS; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; SIGNAL TRANSDUCTION;

EID: 84878312973     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.113.003058     Document Type: Review

References (20)

1. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell. 1993; 75: 843-854.
2. Ambros V. Development: dicing up RNAs. Science. 2001; 293: 811-813.
3. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113: 673-676.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120: 15-20.
5. Ganesan J, Ramanujam D, Sassi Y, Ahles A, Jentzsch C, Werfel S, Leierseder S, Loyer X, Giacca M, Zentilin L, Thum T, Laggerbauer B, Engelhardt S. MiR-378 controls cardiac hypertrophy by combined repression of mitogen-activated protein kinase pathway factors. Circulation. 2013; 127: 2097-2106.
6. Busk PK, Cirera S. MicroRNA profiling in early hypertrophic growth of the left ventricle in rats. Biochem Biophys Res Commun. 2010; 396: 989-993.
7. Bagnall RD, Tsoutsman T, Shephard RE, Ritchie W, Semsarian C. Global microRNA profiling of the mouse ventricles during development of severe hypertrophic cardiomyopathy and heart failure. PLoS One. 2012; 7:e44744.
8. Shen E, Diao X, Wang X, Chen R, Hu B. MicroRNAs involved in the mitogen-activated protein kinase cascades pathway during glucose-induced cardiomyocyte hypertrophy. Am J Pathol. 2011; 179: 639-650.
9. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008; 456: 980-984.
10. Fang J, Song XW, Tian J, Chen HY, Li DF, Wang JF, Ren AJ, Yuan WJ, Lin L. Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes. Apoptosis. 2012; 17: 410-423.
11. Nagalingam RS, Sundaresan NR, Gupta MP, Geenen D, Solaro RJ, Gupta M. A cardiac enriched microRNA, miR-378 blocks cardiac hypertrophy by targeting Ras-signaling. J Biol Chem. 2013; 288: 11216-11232.
12. Davis BN, Hata A. Regulation of microRNA biogenesis: a miRiad of mechanisms. Cell Commun Signal. 2009; 7: 18.
13. Latronico MV, Condorelli G. microRNAs in hypertrophy and heart failure. Exp Biol Med (Maywood). 2011; 236: 125-131.
14. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007; 316: 575-579.
15. Malumbres M. miRNAs versus oncogenes: the power of social networking. Mol Syst Biol. 2012; 8: 569.
16. Uhlmann S, Mannsperger H, Zhang JD, Horvat EÁ, Schmidt C, Küblbeck M, Henjes F, Ward A, Tschulena U, Zweig K, Korf U, Wiemann S, Sahin O. Global microRNA level regulation of EGFR-driven cell-cycle protein network in breast cancer. Mol Syst Biol. 2012; 8: 570.
17. Park CY, Choi YS, McManus MT. Analysis of microRNA knockouts in mice. Hum Mol Genet. 2010; 19: R169-R175.
18. van Rooij E, Olson EN. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat Rev Drug Discov. 2012; 11: 860-872.
19. Jackson AL, Levin AA. Developing microRNA therapeutics: approaching the unique complexities. Nucleic Acid Ther. 2012; 22: 213-225.
20. van Rooij E, Purcell AL, Levin AA. Developing microRNA therapeutics. Circ Res. 2012; 110: 496-507.